Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, among Indian patients with triple-negative breast cancer, Ki-67 expression levels were high but not significantly associated with treatment response to a neoadjuvant docetaxel-carboplatin regimen, which showed complete clinical, imaging, and pathological response rates of 39.13%, 34.78%, and 47.61%, respectively.

Low-dose oral minoxidil combined with topical minoxidil improves hair density in breast cancer patients but may cause excess hair growth.

This paper reviews scalp cooling as an effective method for preventing chemotherapy-induced alopecia, highlighting recent trials that demonstrate its ability to preserve and regrow hair, thus improving patient well-being.

This study investigated the cytotoxic effects of DHA derivatives on cancer cell lines and found that didocosahexaenoin was the most potent, inducing apoptosis and producing reactive oxygen species in PC3 prostate carcinoma cells.

This study will evaluate the clinical efficacy, patient-reported outcomes, and economic impact of the PAXMAN® PSCS 2 automated scalp cooling system versus standard cold-cap therapy to prevent chemotherapy-induced hair loss in women with localized breast cancer during anthracycline and taxane treatment.

In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.

This study observed that while the androgen receptor is expressed in 65.6% of breast cancer patients in Iraq, it is not significantly associated with conventional clinicopathological characteristics, suggesting limited prognostic value.

In this study, broccoli sprout extract and sulforaphane were found to reduce cell viability, suppress growth, and induce apoptosis in breast cancer cells, and oral broccoli sprout extract inhibited tumor growth in animal models, suggesting it may be effective in managing breast cancer.

This study found that combining the PAXMAN scalp cooling system with HairRepro MEDI α lotion led to a 50% success rate in reducing chemotherapy-induced alopecia and achieved complete hair regrowth by 3 months in Japanese breast cancer patients, suggesting enhanced efficacy over scalp cooling alone.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This study observed that spiritual well-being significantly correlates with quality of life aspects in newly diagnosed Palestinian women with breast cancer, where factors like inner peace and faith predicted better body image and reduced distress from hair loss.

This study highlights conflicting evidence on the safety and efficacy of nutritional supplements for hair loss in breast cancer patients, emphasizing the need for oncologist management and further research.

This study found that participants with HR-positive/HER2-negative advanced or metastatic breast cancer treated with sacituzumab govitecan had better quality of life and longer survival compared to standard chemotherapy recipients.

In this study, the ethyl acetate extract of Semecarpus anacardium Linn leaves was reported to induce cytotoxicity in cancer cells, cause cell cycle arrest, and suppress tumor growth in mice.

In this study, researchers will conduct a randomized, double-blind, multi-center clinical trial to assess the effectiveness of YH0618 granule in preventing chemotherapy-induced hair loss among breast cancer patients, aiming to understand its mechanism related to kidney deficiency in Chinese Medicine. Results are not yet reported.

This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.

This review examines the occurrence of permanent alopecia associated with docetaxel in breast cancer treatment, identifying a reported case of lasting hair loss in one patient.

This study found that persistent significant alopecia was a common side effect following FEC-docetaxel chemotherapy, with a 33.4% global incidence, highlighting the need for awareness and potential preventative measures like cooling caps during treatment.

This study suggests that adding androgens to menopausal hormone therapy may reduce breast cancer risk by counteracting estrogen-driven proliferation in postmenopausal breast tissue.

This study suggests that higher use of phytoestrogen-containing hair and personal care products may increase the association between permanent hair dye, straightener use, and breast cancer risk in black women.

This study suggests that chitosan-enhanced human serum albumin nanoparticles could serve as a safe and effective carrier for delivering anticancer drugs like tamoxifen.

This study found that patient-reported outcomes were similar between neoadjuvant endocrine therapy and chemotherapy in premenopausal breast cancer patients, but future perspective was significantly better with endocrine therapy.

This study observed that the molecular structure of keratins in hair fibres' discrete transition zone differs in breast cancer patients, with altered lipid ester absorption bands reverting post-cancer removal.

This phase Ib study found that combining pegylated liposomal doxorubicin and pembrolizumab was well-tolerated and effective, with durable antitumor responses and a median survival of over two years in heavily pretreated ER-positive metastatic breast cancer patients.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

Oral dutasteride, minoxidil, and finasteride may help reduce hair loss in breast cancer survivors, but more research is needed.

This study reviewed evidence on the role of specific genes (FKBP12, SAMAHD1, TRF2, CD155, and GATA3) in predicting how breast cancer patients might respond to adjuvant chemotherapy, aiming to monitor these markers in blood or tissue samples.

This study found that variations in the genes PDCD4, miR-21, and miR-449b may significantly influence breast cancer progression, with higher PDCD4 serum levels linked to increased breastfeeding.

This review discusses the limited evidence on the efficacy of platelet-rich plasma for treating endocrine therapy-induced and permanent chemotherapy-induced alopecia and reports no new clinical results.